Executive Summary
Dr. Ovid Trifan is an executive clinician-scientist whose career spans the full arc of oncology drug development — from target identification and validation, drug discovery, and IND-enabling research, through first-in-human trials, signal-searching Phase 2 programs, and global registrational strategy. With an MD and a PhD in cell biology and formal oncology clinical research training, he pairs deep translational science with the operational discipline of a serial Chief Medical Officer.
As a Senior Partner at The Bracken Group, Ovid advises biotech and pharma clients on clinical development strategy, early-phase oncology programs, portfolio prioritization, IND planning, study design, and organizational scaling, while supporting investor communications, program diligence, and clinical development governance. His therapeutic reach spans oncology, immuno-oncology, and radiopharmaceuticals, with hands-on experience building clinical development and clinical operations functions from the ground up, launching first-in-human diagnostic and therapeutic studies, and standing up international clinical site networks to accelerate enrollment and regulatory timelines.
Across roles at Alpha-9 Oncology, Totus Medicines, TRex Bio, Apexigen, Onyx, Bristol Myers Squibb, and Johnson & Johnson, Ovid has contributed to landmark regulatory submissions — including the ixabepilone NDA and cetuximab filings in head & neck, colorectal, and lung cancer — architected entire clinical programs from pre-IND onward, and served as scientific and clinical spokesperson for investors, partners, and key opinion leaders. Clients engage Ovid when an oncology or radiopharmaceutical program needs a physician-executive who can connect first-in-human science to a credible path to approval.
Areas of Expertise
Oncology Drug Development
End-to-end development across solid tumors — target identification and validation, drug discovery, IND-enabling work, and Phase 1–3 execution through registration.
Immuno-Oncology
CD40 agonist antibody programs (APX005M / sotigalimab), checkpoint and myeloid-targeted combinations, and regulatory T-cell biology across multiple tumor types.
Radiopharmaceuticals & Theranostics
Clinical and operational build-out for radiopharmaceutical oncology assets — first-in-human diagnostic, therapeutic, and Phase 0 studies of biodistribution, uptake, and antitumor activity.
Clinical Development Strategy
Phase 1–3 and registrational trial design, portfolio prioritization, target product profile logic, and clinical/regulatory roadmaps executed capital-efficiently.
First-in-Human & Early-Phase Trials
First-in-human dose escalation with alternative schedules for rapid PK/PD profiling, optimal-window determination, and broad Phase 2 signal-searching programs.
Medical Monitoring & Drug Safety
Medical monitoring across Phase 1–3 oncology trials, safety surveillance and signal evaluation, and protocol and amendment authoring — from first-in-human dosing through registrational studies.
Regulatory & NDA / BLA Strategy
FDA and global submissions, including the ixabepilone NDA and cetuximab filings in head & neck, colorectal, and non-small cell lung cancer across the US and Canada.
Companion Diagnostics & Biomarkers
Biomarker-driven trial design and companion diagnostic strategy — βIII-tubulin IHC and KRAS mutation assays — linking patient selection to registration intent.
Business Development & Due Diligence
Scientific and clinical spokesperson for investor presentations, partnership discussions, asset acquisition assessment, and fundraising-facing materials.